Michael Bogenschutz

Michael P. Bogenschutz is a psychiatrist and clinical researcher known for pioneering clinical trials of psychedelic-assisted therapies, particularly psilocybin-assisted psychotherapy for alcohol use disorder (AUD). He has served as a principal investigator on randomized, double-blind, placebo-controlled trials examining psilocybin's safety, efficacy, and longer-term effects in patients with AUD, and has published on multidimensional outcomes including changes in drinking behaviour, personality, and spiritual/phenomenological experiences. His clinical work spans trials in substance use disorders, cancer-related anxiety, and contributions to broader efforts in MDMA-assisted therapy and other psychedelic modalities.

Beyond clinical trials, Bogenschutz has co-developed manualised psychotherapeutic approaches for psychedelic-assisted treatment, contributed to methodological discussions about training and therapist roles, and reported on qualitative and case-study evidence (for example, spiritual experiences and individual patient narratives) that illuminate therapeutic processes. He has also explored population-level and religious contexts of psychedelic use (for example, work on ayahuasca use in religious settings), positioning his work at the interface of rigorous clinical research, clinical practice development, and phenomenological analysis of psychedelic experiences.